<code id='5936E3F333'></code><style id='5936E3F333'></style>
    • <acronym id='5936E3F333'></acronym>
      <center id='5936E3F333'><center id='5936E3F333'><tfoot id='5936E3F333'></tfoot></center><abbr id='5936E3F333'><dir id='5936E3F333'><tfoot id='5936E3F333'></tfoot><noframes id='5936E3F333'>

    • <optgroup id='5936E3F333'><strike id='5936E3F333'><sup id='5936E3F333'></sup></strike><code id='5936E3F333'></code></optgroup>
        1. <b id='5936E3F333'><label id='5936E3F333'><select id='5936E3F333'><dt id='5936E3F333'><span id='5936E3F333'></span></dt></select></label></b><u id='5936E3F333'></u>
          <i id='5936E3F333'><strike id='5936E3F333'><tt id='5936E3F333'><pre id='5936E3F333'></pre></tt></strike></i>

          Home / hotspot / leisure time

          leisure time


          leisure time

          author:explore    Page View:4863
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In